

PRESS RELEASE

Stockholm 25 February, 2026

TikoMed signs letter of intent with Karolinska Institutet on myocardial infarction study

The Department of Medicine Solna at Karolinska Institutet and TikoMed AB have signed a letter of intent for a collaboration on a clinical study of ILB® in myocardial infarction. The study is called ILBIAMI and the aim is to evaluate the effect of ILB® in counteracting the consequences of myocardial infarction by limiting the extent of heart muscle damage. Karolinska Institutet will be the sponsor of the study, while TikoMed is responsible for providing the active product and placebo substance as well as scientific support for the product.

The study is the first clinical study with ILB® in this field. The scientists will now apply for approval for the study, which is expected to start in 2026.

‘There are promising data from animal experiments in this indication, which has piqued our interest’, says Lars Rydén, professor emeritus of cardiology and active at the Karolinska University Hospital and initiator of the study. ‘Although much has happened in myocardial infarction care in recent decades, there is still potential for improvement’, Prof Rydén adds.

‘It is a big leap for us as a company to collaborate with Karolinska Institutet on this important study’, says Dr Björn Pilström, CEO and Chief Medical Officer at TikoMed. ‘Hopefully, the study will confirm the animal data that have previously indicated a positive effect of ILB® in myocardial infarction’, Dr Pilström continues.

About TikoMed AB

TikoMed is a Swedish biotechnology company focused on developing innovative treatments based on the ILB® platform. The company manufactures ILB® and conducts research in acute and chronic disease conditions with considerable unmet medical need.

About the Department of Medicine Solna, Karolinska Institutet

The Department of Medicine Solna is one of the largest research and educational departments at Karolinska Institutet, with leading clinical and translational research in areas such as cardiology, immunology and inflammatory diseases.